COM:IMMATICS
Immatics
- Stock
market
STOCKSindustry
Biopharmaceuticalswebsite
immatics.comcrunchbase
immatics-biotechnologiesipo date
Dec 12, 2018
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-...Show More